Estimates of the global burden of Japanese encephalitis and the impact of vaccination from 2000-2015

Japanese encephalitis (JE) is a mosquito-borne disease, known for its high mortality and disability rate among symptomatic cases. Many effective vaccines are available for JE, and the use of a recently developed and inexpensive vaccine, SA 14-14-2, has been increasing over the recent years particula...

Full description

Saved in:
Bibliographic Details
Published ineLife Vol. 9
Main Authors Quan, Tran Minh, Thao, Tran Thi Nhu, Duy, Nguyen Manh, Nhat, Tran Minh, Clapham, Hannah
Format Journal Article
LanguageEnglish
Published England eLife Sciences Publications Ltd 26.05.2020
eLife Sciences Publications, Ltd
Subjects
Age
Encephalitis
Encephalitis, Japanese - epidemiology
Encephalitis, Japanese - prevention & control
Endemic Diseases
Epidemiology and Global Health
Estimates
Global Burden of Disease
Humans
Infections
japanese encephalitis
Japanese Encephalitis Vaccines
mathematical modelling
Mathematical models
Mosquitoes
Surveillance
Systematic review
Vaccination
vaccination impact
Vaccines
Vector-borne diseases
Working groups
Asia
Japan
Nepal
Taiwan
global health
epidemiology
vaccination impact
mathematical modelling
human
japanese encephalitis
Online AccessGet full text

Cover

More Information
Summary:Japanese encephalitis (JE) is a mosquito-borne disease, known for its high mortality and disability rate among symptomatic cases. Many effective vaccines are available for JE, and the use of a recently developed and inexpensive vaccine, SA 14-14-2, has been increasing over the recent years particularly with Gavi support. Estimates of the local burden and the past impact of vaccination are therefore increasingly needed, but difficult due to the limitations of JE surveillance. In this study, we implemented a mathematical modelling method (catalytic model) combined with age-stratifed case data from our systematic review which can overcome some of these limitations. We estimate in 2015 JEV infections caused 100,308 JE cases (95% CI: 61,720-157,522) and 25,125 deaths (95% CI: 14,550-46,031) globally, and that between 2000 and 2015 307,774 JE cases (95% CI: 167,442-509,583) were averted due to vaccination globally. Our results highlight areas that could have the greatest benefit from starting vaccination or from scaling up existing programs and will be of use to support local and international policymakers in making vaccine allocation decisions.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore.
ISSN:2050-084X
2050-084X
DOI:10.7554/eLife.51027